A Phase 1, Single-Dose Study to Assess the Relative Bioavailability, Absolute Bioavailability, and Tolerability of LY3074828 Formulations in Healthy Subjects

Trial Profile

A Phase 1, Single-Dose Study to Assess the Relative Bioavailability, Absolute Bioavailability, and Tolerability of LY3074828 Formulations in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
  • Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
    • 18 May 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top